Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer

Full text
Author(s):
Favaro, Wagner J. [1, 2] ; Nunes, Odilon S. [1] ; Seiva, Fabio R. F. [2] ; Nunes, Iseu S. [1] ; Woolhiser, Lisa K. [3] ; Duran, Nelson [1, 4, 5] ; Lenaerts, Anne J. [3]
Total Authors: 7
Affiliation:
[1] Farmabrasilis R&D Div, Campinas, SP - Brazil
[2] Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, BR-61091308 Campinas, SP - Brazil
[3] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 - USA
[4] Univ Estadual Campinas, UNICAMP, Inst Chem, Biol Chem Lab, Campinas, SP - Brazil
[5] Univ Fed do ABC, Ctr Nat & Human Sci, Santo Andre, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: INFECTIOUS AGENTS AND CANCER; v. 7, JUN 18 2012.
Web of Science Citations: 21
Abstract

Background: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for the development of drugs against infectious diseases and cancer. The present study aimed to characterize the immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant therapy in infectious diseases and cancer. Methods: For these purposes, the activity of P-MAPA on TLRs was assayed in vitro through NF-kappa B activation in HEK293 cells expressing a given TLR, and using an in vivo animal model for bladder cancer (BC). The antimicrobial activity of P-MAPA was tested against Mycobacterium tuberculosis (TB) in vitro in an MIC assay, and in vivo using an aerosol infection model of murine tuberculosis. Antitumor effects of P-MAPA were tested in an animal model with experimentally induced BC. Moxifloxacin (MXF) and Bacillus Calmette-Guerin (BCG) were used as positive controls in the animal models. Results: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant responses in vivo against TB. In contrast, the compound did not show antimicrobial activity in vitro. P-MAPA showed a significant stimulatory effect on human TLR2 and TLR4 in vitro. In BC, TLR2, TLR4 and p53 protein levels were significantly higher in the P-MAPA group than in the BCG group. The most common histopathological changes in each group were papillary carcinoma in BC group, low-grade intraepithelial neoplasia in BCG group and simple hyperplasia in P-MAPA group. Concerning the toxicological analysis performed during BC treatment, P-MAPA did not show evidence for hepatotoxicity and nephrotoxicity. Conclusions: In conclusion, P-MAPA acted as TLR ligand in vitro and improved the immunological status in BC, increasing TLR2 and TLR4 protein levels. P-MAPA immunotherapy was more effective in restoring p53 and TLRs reactivities and showed significantly greater antitumor activity than BCG. The activation of TLRs and p53 may provide a hypothetical mechanism for the therapeutic effects in both cancer and infectious diseases. Taken together data obtained will encourage the further investigation of P-MAPA as a potential candidate for the treatment of cancer and infectious diseases. (AU)

FAPESP's process: 11/05726-4 - Oxidative Stress, Antioxidant Enzyme Activities and Toll-Like Receptors 2 and 4 Signaling Pathway in Urinary Bladder Cancer Progression of Rats Submitted to Bacillus Calmette-Guerin and P-MAPA Intravesical Immunotherapies.
Grantee:Fábio Rodrigues Ferreira Seiva
Support Opportunities: Scholarships in Brazil - Post-Doctoral